Perrigo Company plc (NYSE:PRGO) Shares Acquired by Voisard Asset Management Group Inc.

Voisard Asset Management Group Inc. lifted its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 9.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,100 shares of the company’s stock after buying an additional 450 shares during the quarter. Voisard Asset Management Group Inc.’s holdings in Perrigo were worth $134,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in PRGO. Dimensional Fund Advisors LP increased its position in shares of Perrigo by 3.6% during the second quarter. Dimensional Fund Advisors LP now owns 7,162,656 shares of the company’s stock worth $183,935,000 after purchasing an additional 249,640 shares in the last quarter. Deprince Race & Zollo Inc. increased its position in shares of Perrigo by 11.2% during the second quarter. Deprince Race & Zollo Inc. now owns 3,882,438 shares of the company’s stock worth $99,701,000 after purchasing an additional 391,646 shares in the last quarter. Cooke & Bieler LP increased its position in shares of Perrigo by 0.9% during the second quarter. Cooke & Bieler LP now owns 3,501,401 shares of the company’s stock worth $89,916,000 after purchasing an additional 30,150 shares in the last quarter. DAVENPORT & Co LLC grew its holdings in Perrigo by 10.1% in the 1st quarter. DAVENPORT & Co LLC now owns 3,449,352 shares of the company’s stock valued at $111,035,000 after buying an additional 317,552 shares in the last quarter. Finally, Copeland Capital Management LLC grew its holdings in Perrigo by 23.1% in the 3rd quarter. Copeland Capital Management LLC now owns 2,482,544 shares of the company’s stock valued at $65,117,000 after buying an additional 465,161 shares in the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

Perrigo Stock Performance

NYSE PRGO opened at $25.43 on Thursday. The stock has a market cap of $3.47 billion, a PE ratio of -363.29 and a beta of 0.48. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 0.80. Perrigo Company plc has a twelve month low of $23.89 and a twelve month high of $34.60. The stock has a fifty day simple moving average of $26.53 and a 200-day simple moving average of $27.67.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Friday, August 2nd. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. During the same period in the prior year, the business posted $0.63 EPS. The company’s revenue was down 10.7% compared to the same quarter last year. Equities analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. StockNews.com cut Perrigo from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Jefferies Financial Group restated a “hold” rating and issued a $30.00 target price (down from $50.00) on shares of Perrigo in a report on Monday, September 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $42.00 target price on shares of Perrigo in a report on Monday, September 30th. Finally, Piper Sandler dropped their target price on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Perrigo has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Insider Buying and Selling

In related news, EVP Ronald Craig Janish sold 13,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $29.40, for a total transaction of $382,200.00. Following the transaction, the executive vice president now owns 20,553 shares of the company’s stock, valued at approximately $604,258.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Perrigo news, EVP Svend Andersen sold 28,300 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $27.75, for a total value of $785,325.00. Following the sale, the executive vice president now owns 73,553 shares of the company’s stock, valued at $2,041,095.75. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ronald Craig Janish sold 13,000 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $29.40, for a total value of $382,200.00. Following the completion of the sale, the executive vice president now directly owns 20,553 shares in the company, valued at $604,258.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,254 shares of company stock valued at $1,411,969. Corporate insiders own 0.70% of the company’s stock.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.